StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Sunday. The firm issued a sell rating on the stock.

SYRS has been the subject of several other reports. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Syros Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ SYRS opened at $0.21 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $8.17. The stock has a market capitalization of $5.61 million, a price-to-earnings ratio of -0.07 and a beta of 1.33. The business’s fifty day moving average price is $1.31 and its 200-day moving average price is $3.00.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm earned ($1.35) earnings per share. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Acadian Asset Management LLC raised its stake in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter valued at approximately $109,000. Exome Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.